JP2007320958A - Prophylactic and/or curative agent for fatty liver - Google Patents
Prophylactic and/or curative agent for fatty liver Download PDFInfo
- Publication number
- JP2007320958A JP2007320958A JP2007121049A JP2007121049A JP2007320958A JP 2007320958 A JP2007320958 A JP 2007320958A JP 2007121049 A JP2007121049 A JP 2007121049A JP 2007121049 A JP2007121049 A JP 2007121049A JP 2007320958 A JP2007320958 A JP 2007320958A
- Authority
- JP
- Japan
- Prior art keywords
- extracted
- butanol
- fraction
- molecular weight
- polyphenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、天然由来の脂肪肝の予防および／または治療剤に関する。 The present invention relates to a prophylactic and / or therapeutic agent for naturally occurring fatty liver.
脂肪肝は、アルコールの過剰摂取、過栄養、糖尿病などを起因として肝細胞内に脂質が多量に蓄積した状態をいい、慢性肝炎や肝硬変や肝癌などの原因になることから、その予防や治療が重要視されている。従って、脂肪肝の予防や治療に効果がある薬剤の研究開発が精力的に行われており、例えば、特許文献１にはアンジオテンシン変換酵素阻害剤が脂肪肝の予防や治療に効果があることが記載されている。
しかしながら、脂肪肝に対して優れた効果を有するとともに安全な薬剤の探求は意義深いことである。
そこで本発明は、天然由来の脂肪肝の予防および／または治療剤を提供することを目的とする。
However, the search for a safe drug that has an excellent effect on fatty liver is significant.
Accordingly, an object of the present invention is to provide a preventive and / or therapeutic agent for naturally occurring fatty liver.
本発明者らは、上記の点に鑑みて鋭意研究を重ねた結果、発酵茶から抽出される高分子ポリフェノールが脂肪肝の予防や治療に有効であることを見出した。 As a result of intensive studies in view of the above points, the present inventors have found that a polymer polyphenol extracted from fermented tea is effective for the prevention and treatment of fatty liver.
上記の知見に基づいてなされた本発明の脂肪肝の予防および／または治療剤は、請求項１記載の通り、発酵茶から抽出される高分子ポリフェノールを有効成分とすることを特徴とする。
また、請求項２記載の予防および／または治療剤は、請求項１記載の予防および／または治療剤において、高分子ポリフェノールが、プロシアニジン構造と、カテキン類のＢ環同士が結合した構造を部分構造中に少なくとも含んでおり、数平均分子量が９０００〜１８０００であることを特徴とする。
また、請求項３記載の予防および／または治療剤は、請求項１または２記載の予防および／または治療剤において、高分子ポリフェノールが、発酵茶葉中の水溶出成分を酢酸エチル抽出し、抽出されなかった酢酸エチル非溶出成分をブタノール抽出し、抽出されたブタノール溶出成分を溶媒に含水アセトンを用いて分画精製することで得られてなることを特徴とする。
また、請求項４記載の予防および／または治療剤は、請求項１または２記載の予防および／または治療剤において、高分子ポリフェノールが、発酵茶葉中の水溶出成分を酢酸エチル抽出し、抽出されなかった酢酸エチル非溶出成分をブタノール抽出し、抽出されなかったブタノール非溶出成分を酸性化した後に再びブタノール抽出し、抽出されたブタノール溶出成分を溶媒に含水アセトンを用いて分画精製することで得られてなることを特徴とする。
また、請求項５記載の予防および／または治療剤は、請求項１乃至３のいずれかに記載の予防および／または治療剤において、発酵茶がウーロン茶または紅茶であることを特徴とする。
The preventive and / or therapeutic agent for fatty liver of the present invention based on the above findings is characterized in that, as described in claim 1, high molecular polyphenol extracted from fermented tea is an active ingredient.
Further, the preventive and / or therapeutic agent according to claim 2 is the prophylactic and / or therapeutic agent according to claim 1, wherein the polymer polyphenol has a partial structure having a structure in which a procyanidin structure and B rings of catechins are bonded to each other. The number average molecular weight is 9000 to 18,000.
Further, the preventive and / or therapeutic agent according to claim 3 is the prophylactic and / or therapeutic agent according to claim 1 or 2, wherein the polymer polyphenol is extracted by extracting the water-eluting component in the fermented tea leaves with ethyl acetate. The non-eluting component of ethyl acetate that has not been extracted is extracted with butanol, and the extracted butanol-eluting component is obtained by fractional purification using water-containing acetone as a solvent.
Further, the preventive and / or therapeutic agent according to claim 4 is the same as the prophylactic and / or therapeutic agent according to claim 1 or 2, wherein the polymer polyphenol is extracted by extracting the water-eluting component in the fermented tea leaves with ethyl acetate. Extract the non-eluting components of ethyl acetate with butanol, acidify the non-eluting components of butanol that were not extracted, and then extract with butanol again, and fractionate and purify the extracted butanol-eluting components using aqueous acetone as a solvent. It is characterized by being obtained.
The preventive and / or therapeutic agent according to claim 5 is characterized in that in the prophylactic and / or therapeutic agent according to any one of claims 1 to 3, the fermented tea is oolong tea or black tea.
本発明によれば、天然由来の脂肪肝の予防および／または治療剤を提供することができる。 According to the present invention, a prophylactic and / or therapeutic agent for naturally occurring fatty liver can be provided.
本発明の脂肪肝の予防および／または治療剤は、発酵茶から抽出される高分子ポリフェノールを有効成分とすることを特徴とするものである。本発明において、発酵茶とは、茶葉の発酵を進行させてなる茶を意味し、その具体例としては、半発酵茶であるウーロン茶や発酵茶である紅茶などが挙げられる。また、本発明において、高分子ポリフェノールとは、分子内にフェノール性水酸基を複数個有する化合物、例えば、フラボノイド系ポリフェノールであるカテキン類が高度に重合したもの（例えば数平均分子量が５０００〜３００００）を意味する。カテキン類は、Ｃ６−Ｃ３−Ｃ６骨格にフェノール系水酸基を複数個有するフラバン−３−オール骨格を持つ化合物群であり、特に、茶の葉に多く含まれることは当業者によく知られた事実である。カテキンの化学構造は下記に示す通りである。カテキンには様々な誘導体が存在する（例えばカテキンの５’位の水素が水酸基に置換されたものがガロカテキンであり、さらに３位の水酸基が没食子酸とエステル結合したものがガロカテキンガレートである）。本発明において、カテキン類とは、カテキンおよびその誘導体を意味し、その具体例としては、カテキン、カテキンガレート、エピカテキン、エピカテキンガレート、ガロカテキン、ガロカテキンガレート、エピガロカテキン、エピガロカテキンガレートなどが挙げられる。 The preventive and / or therapeutic agent for fatty liver according to the present invention is characterized by comprising a high-molecular polyphenol extracted from fermented tea as an active ingredient. In the present invention, fermented tea means tea obtained by causing fermentation of tea leaves, and specific examples thereof include oolong tea that is semi-fermented tea and black tea that is fermented tea. In the present invention, the high molecular polyphenol is a compound in which a compound having a plurality of phenolic hydroxyl groups in the molecule, for example, catechins that are flavonoid polyphenols are highly polymerized (for example, the number average molecular weight is 5000 to 30000). means. Catechins are a group of compounds having a flavan-3-ol skeleton having a plurality of phenolic hydroxyl groups in the C 6 -C 3 -C 6 skeleton, and are particularly well known to those skilled in the art that they are contained in large amounts in tea leaves. It is the fact that was done. The chemical structure of catechin is as shown below. There are various derivatives of catechin (for example, galcatechin in which hydrogen at the 5′-position of catechin is substituted with a hydroxyl group, and galcatechin gallate in which the hydroxyl group at the 3-position is ester-bonded with gallic acid) . In the present invention, catechins mean catechin and derivatives thereof, and specific examples thereof include catechin, catechin gallate, epicatechin, epicatechin gallate, gallocatechin, gallocatechin gallate, epigallocatechin gallate, etc. Is mentioned.
発酵茶から抽出される高分子ポリフェノールは、発酵茶の製造過程（発酵や熟成など）でカテキン類が高度に重合することで生成すると考えられるものであり、その取得方法としては、例えば、発酵茶葉中の水溶出成分（水、沸騰水、熱水、水蒸気などで抽出することで溶出する成分）を酢酸エチル抽出し、抽出されなかった酢酸エチル非溶出成分をブタノール抽出し、抽出されたブタノール溶出成分を溶媒に含水アセトンを用いて分画精製する方法や、発酵茶葉中の水溶出成分を酢酸エチル抽出し、抽出されなかった酢酸エチル非溶出成分をブタノール抽出し、抽出されなかったブタノール非溶出成分を酸性化した後に再びブタノール抽出し、抽出されたブタノール溶出成分を溶媒に含水アセトンを用いて分画精製する方法などが挙げられる。なお、溶媒に含水アセトンを用いた分画精製は、例えば東ソー株式会社のトヨパールＨＷ−４０Ｆを用いたゲルろ過クロマトグラフィーにより行うことができる。
また、発酵茶から抽出される高分子ポリフェノールは、水や、メタノールやエタノールやアセトンなどの有機溶媒を用いた抽出操作によって得られる発酵茶葉抽出物を合成吸着剤（例えば芳香族系合成吸着剤である三菱化学株式会社のダイヤイオンＨＰ２０など）に吸着させ、吸着剤を３０％メタノール溶液などで洗浄した後、７０％メタノール溶液などで吸着成分を溶出し、溶出成分から酢酸エチル溶出成分を除去した後、酢酸エチル非溶出成分を溶媒に含水アセトンを用いてゲルろ過クロマトグラフィーにより分画精製する方法などによっても取得することができる。
Polymer polyphenols extracted from fermented tea are thought to be produced by highly polymerizing catechins in the production process of fermented tea (fermentation, ripening, etc.). As an acquisition method thereof, for example, fermented tea leaves Extraction of water-eluted components (components eluted by extraction with water, boiling water, hot water, steam, etc.) with ethyl acetate, extracted non-extracted ethyl acetate with butanol, and extracted with butanol A method of fractionating and purifying components using water-containing acetone as a solvent, and extracting water-eluted components in fermented tea leaves with ethyl acetate, extracting non-extracted ethyl acetate with butanol, and extracting non-butanol with non-extracted butanol Examples include a method in which butanol is extracted again after acidifying the components, and the extracted butanol-eluting components are fractionated and purified using aqueous acetone as a solvent. . In addition, fractional purification using water-containing acetone as a solvent can be performed, for example, by gel filtration chromatography using Toyopearl HW-40F manufactured by Tosoh Corporation.
In addition, high-molecular polyphenols extracted from fermented tea can be obtained by converting fermented tea leaf extracts obtained by extraction operations using water, organic solvents such as methanol, ethanol, and acetone into synthetic adsorbents (for example, aromatic synthetic adsorbents). Adsorbed on a certain Mitsubishi Chemical Corporation Diaion HP20, etc., and after washing the adsorbent with a 30% methanol solution, etc., the adsorbed component was eluted with a 70% methanol solution, etc., and the ethyl acetate eluting component was removed from the eluted component. Subsequently, the ethyl acetate non-eluting component can also be obtained by a method of fractional purification by gel filtration chromatography using hydrous acetone as a solvent.
発酵茶から抽出される高分子ポリフェノールの具体例としては、プロシアニジン構造と、カテキン類のＢ環同士が結合した構造を部分構造中に少なくとも含んでおり、数平均分子量が９０００〜１８０００であるものが挙げられる。プロシアニジン構造とは、カテキン類のＣ環と他のカテキン類のＡ環が結合した構造である。発酵茶から抽出される高分子ポリフェノールは、プロシアニジン構造と、カテキン類のＢ環同士が結合した構造の他に、カテキン類のＢ環と他のカテキン類のＡ環が結合した構造などを含んでいてもよい。発酵茶から抽出される高分子ポリフェノールが有する部分構造の具体例としては以下に示すものが挙げられる。なお、以下に示す部分構造はあくまで例示に過ぎず、発酵茶から抽出される高分子ポリフェノールは、ベンゾトロポロン、ベンゾキノン、ナフトキノンなどを含む部分構造をはじめとする多種多様の部分構造を有するものと考えられる。 Specific examples of the high molecular weight polyphenol extracted from fermented tea include a procyanidin structure and a structure in which B rings of catechins are bonded to each other in a partial structure, and the number average molecular weight is 9000 to 18000. Can be mentioned. The procyanidin structure is a structure in which the C ring of catechins and the A ring of other catechins are bonded. Polymer polyphenols extracted from fermented tea include a procyanidin structure and a structure in which the B rings of catechins are bonded to each other, as well as a structure in which the B ring of catechins and the A ring of other catechins are bonded. May be. Specific examples of the partial structure of the polymer polyphenol extracted from fermented tea include the following. The partial structures shown below are merely examples, and the polymer polyphenol extracted from fermented tea is considered to have a wide variety of partial structures including partial structures including benzotropolone, benzoquinone, naphthoquinone, and the like. It is done.
本発明の脂肪肝の予防および／または治療剤は、発酵茶から抽出される高分子ポリフェノールを自体公知の方法によって顆粒剤や錠剤やカプセル剤などの経口製剤に製剤化したり、注射剤などの非経口製剤に製剤化したりしてヒトを含む哺乳動物に投与することで、脂肪肝の予防や治療に優れた効果を発揮する。その投与量は、適用対象の年齢、性別、体重、体調、脂肪肝の程度などによって適宜決定することができる。また、本発明の脂肪肝の予防および／または治療剤は、発酵茶から抽出される高分子ポリフェノールを種々の形態の食品（サプリメントを含む）に脂肪肝の予防や治療に効果をもたらすに足る有効量を添加することで、機能性食品として食してもよい。 The preventive and / or therapeutic agent for fatty liver according to the present invention is prepared by formulating a high molecular polyphenol extracted from fermented tea into an oral preparation such as a granule, a tablet or a capsule by a method known per se, or a non-injection such as an injection. When formulated into oral preparations and administered to mammals including humans, it exhibits excellent effects in the prevention and treatment of fatty liver. The dose can be appropriately determined depending on the age, sex, weight, physical condition, degree of fatty liver, etc. of the application target. Moreover, the preventive and / or therapeutic agent for fatty liver of the present invention is effective enough to bring high-molecular polyphenols extracted from fermented tea to various forms of food (including supplements) for the prevention and treatment of fatty liver. You may eat as a functional food by adding quantity.
以下、本発明を実施例によって詳細に説明するが、本発明は以下の記載によって何ら限定して解釈されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, this invention is not limited at all by the following description.
実施例１：ウーロン茶から抽出される高分子ポリフェノール（その１）の脂肪肝に対する作用
（Ａ）ウーロン茶から抽出される高分子ポリフェノールの調製
沸騰水１０００ｍＬにウーロン茶葉３０ｇを加え、約１分間沸騰後、１０分間静置した。その後、ウーロン茶葉をろ過して除去し、ろ液を得た。以上の操作を合計４回行い、ウーロン茶葉１２０ｇから水溶出成分を含む水溶液を得た。
次に、水溶出成分から低分子ポリフェノールを除去するために酢酸エチル抽出した。具体的には、水溶液５００ｍＬにつき２００ｍＬの水飽和酢酸エチルを加え、攪拌し、静置した後、酢酸エチル相を分取する操作を１０回繰り返し、酢酸エチル非溶出成分を含む水相を得た。
次に、酢酸エチル非溶出成分を含む水相をブタノール抽出した。具体的には、水相を減圧濃縮することで残存する酢酸エチルを除去した後、５００ｍＬにつき２００ｍＬの水飽和ｎ−ブタノールを加え、攪拌し、静置した後、ブタノール相を分取する操作を１０回繰り返した。分取したブタノール相を集めることでブタノール溶出成分を含む抽出液を得、これを減圧濃縮することで残存するブタノールを除去し、ブタノール溶出成分を含む水溶液を得た。この水溶液を凍結乾燥し、ウーロン茶ブタノール抽出中性画分をウーロン茶葉１２０ｇあたり４．５ｇの収量で得た。
Example 1: Action of high-molecular polyphenol extracted from oolong tea (part 1) on fatty liver (A) Preparation of high-molecular polyphenol extracted from oolong tea 30 g of oolong tea leaf was added to 1000 mL of boiling water and boiled for about 1 minute. Allowed to stand for 10 minutes. Thereafter, the oolong tea leaves were removed by filtration to obtain a filtrate. The above operation was performed 4 times in total to obtain an aqueous solution containing a water-eluting component from 120 g of oolong tea leaves.
Next, extraction with ethyl acetate was performed to remove low molecular weight polyphenols from the water-eluting components. Specifically, 200 mL of water-saturated ethyl acetate was added to 500 mL of an aqueous solution, stirred and allowed to stand, and then the operation of separating the ethyl acetate phase was repeated 10 times to obtain an aqueous phase containing an ethyl acetate non-eluting component. .
Next, the aqueous phase containing non-eluting components of ethyl acetate was extracted with butanol. Specifically, after removing the remaining ethyl acetate by concentrating the aqueous phase under reduced pressure, 200 mL of water-saturated n-butanol was added per 500 mL, stirred, allowed to stand, and then fractionating the butanol phase. Repeated 10 times. By collecting the separated butanol phase, an extract containing a butanol-eluting component was obtained, and this was concentrated under reduced pressure to remove the remaining butanol, thereby obtaining an aqueous solution containing a butanol-eluting component. This aqueous solution was freeze-dried, and a neutral fraction extracted from oolong tea butanol was obtained at a yield of 4.5 g per 120 g of oolong tea leaves.
次に、以上の方法で得られたウーロン茶ブタノール抽出中性画分を、ゲルろ過クロマトグラフィーを行ってさらに細かく分画した。固定相にはトヨパールＨＷ−４０Ｆ（東ソー株式会社製）を用い、移動相には含水アセトンを用いた。
まず、直径２．４ｃｍ×長さ３５ｃｍのカラムにトヨパールＨＷ−４０Ｆを充填した。また、移動相として２０％アセトン溶液と５０％アセトン溶液をそれぞれ６００ｍＬ準備した。
次に、ウーロン茶ブタノール抽出中性画分０．３ｇを２０％アセトン溶液３ｍＬに溶解し、得られた溶液をカラムにアプライした。２０％アセトン溶液と５０％アセトン溶液を用いて固定相に吸着した成分を２０〜５０％の直線的濃度勾配をかけて０．３ｇ／分の速度で順次溶出させ、フラクションコレクターを用いて溶出液を５ｇずつ試験管に分取した。
次に、各試験管に分取した溶出液の３５０ｎｍにおける吸光度を測定し、溶出曲線を作成した。作成した溶出曲線に基づいてウーロン茶ブタノール抽出中性画分をさらに細かく分画し、同じ画分に属する溶出液を集めた後、減圧濃縮することでアセトンを除去し、凍結乾燥し、１５個の画分サンプルを得た。
図１にウーロン茶ブタノール抽出中性画分の溶出曲線（溶出パターン）を示す（横軸：溶出液を回収した試験管番号（回収順），縦軸：３５０ｎｍにおける吸光度）。また、溶出曲線に基づいて細分画して得た１５個の画分を図１にあわせて示す。
Next, the oolong tea butanol-extracted neutral fraction obtained by the above method was further finely fractionated by gel filtration chromatography. Toyopearl HW-40F (manufactured by Tosoh Corporation) was used as the stationary phase, and water-containing acetone was used as the mobile phase.
First, Toyopearl HW-40F was packed in a column having a diameter of 2.4 cm and a length of 35 cm. In addition, 600 mL each of a 20% acetone solution and a 50% acetone solution were prepared as mobile phases.
Next, 0.3 g of a neutral fraction extracted from oolong tea butanol was dissolved in 3 mL of 20% acetone solution, and the resulting solution was applied to a column. The components adsorbed on the stationary phase using a 20% acetone solution and a 50% acetone solution are sequentially eluted at a rate of 0.3 g / min with a linear concentration gradient of 20 to 50%, and an eluate is obtained using a fraction collector. Was dispensed into test tubes in 5-g increments.
Next, the absorbance at 350 nm of the eluate fractionated into each test tube was measured to prepare an elution curve. The neutral fraction extracted from oolong tea butanol was further finely fractionated based on the prepared elution curve, and after collecting the eluate belonging to the same fraction, acetone was removed by concentration under reduced pressure, freeze-dried, and 15 Fraction samples were obtained.
FIG. 1 shows an elution curve (elution pattern) of a neutral fraction extracted from oolong tea butanol (horizontal axis: test tube number from which the eluate was collected (in order of collection), vertical axis: absorbance at 350 nm). 15 fractions obtained by subfractionation based on the elution curve are also shown in FIG.
（Ｂ）画分（１５）の平均分子量の測定
サイズ排除クロマトグラフィー法（ＳＥＣ：ｓｉｚｅ ｅｘｃｌｕｓｉｏｎ ｃｈｒｏｍａｔｏｇｒａｐｈｙ）によって画分（１５）の平均分子量の測定を行った。高速クロマトグラフ装置としてＬＣ−１０Ａシステム（株式会社島津製作所製）を用い、カラムにはＴＳＫ−ＧＥＬα−３０００（カラム寸法：直径７．８ｍｍ×長さ３０ｃｍ，東ソー株式会社製）を用いた。カラム温度は４０℃とした。展開溶媒には塩化リチウム１０ｍＭを含有したジメチルホルムアミドを用いた。流速は０．６ｍＬ／分に設定した。検出器にはＬＣ−１０Ａシステムに含まれるＵＶ検出器を用いた。検出波長は２７５ｎｍに設定した。
まず、カラムに分子量標準化合物としてＴＳＫ標準ポリスチレン（東ソー株式会社製）をアプライし、溶出時間を横軸に、ＵＶ検出値を縦軸にしてプロットし、溶出曲線を作成し、これに基づいて較正曲線を作成した。
次に、カラムにジメチルホルムアミドに溶解した画分（１５）をアプライし、溶出時間を横軸に、ＵＶ検出値を縦軸にしてプロットし、較正曲線に基づいて平均分子量を算出したところ、数平均分子量は１．５２×１０４、重量平均分子量は２．１０×１０４であった。
(B) Measurement of the average molecular weight of the fraction (15) The average molecular weight of the fraction (15) was measured by a size exclusion chromatography method (SEC: size exclusion chromatography). An LC-10A system (manufactured by Shimadzu Corporation) was used as a high-speed chromatograph, and TSK-GELα-3000 (column dimensions: diameter 7.8 mm × length 30 cm, manufactured by Tosoh Corporation) was used as a column. The column temperature was 40 ° C. Dimethylformamide containing 10 mM lithium chloride was used as the developing solvent. The flow rate was set at 0.6 mL / min. The detector used was a UV detector included in the LC-10A system. The detection wavelength was set at 275 nm.
First, TSK standard polystyrene (manufactured by Tosoh Corporation) is applied to the column as a molecular weight standard compound, and the elution time is plotted on the horizontal axis and the UV detection value is plotted on the vertical axis to create an elution curve, and calibration is performed based on this. A curve was created.
Next, a fraction (15) dissolved in dimethylformamide was applied to the column, the elution time was plotted on the horizontal axis, the UV detection value on the vertical axis, and the average molecular weight was calculated based on the calibration curve. The average molecular weight was 1.52 × 10 4 and the weight average molecular weight was 2.10 × 10 4 .
（Ｃ）画分（１５）の構造解析
熱分解−ガスクロマトグラフ−マススペクトル（Ｐｙ−ＧＣ−ＭＳ）分析装置を用いて画分（１５）の構造解析を行った。Ｐｙ−ＧＣ−ＭＳ分析装置によれば、サンプルを熱分解装置（Ｐｙ）で熱分解した後、得られた熱分解生成物をガスクロマトグラフ装置（ＧＣ）に導入して分別し、さらに分別した物質をマススペクトル装置（ＭＳ）で解析することにより、サンプルの熱的性質や化学構造に関する知見を得ることができる。
最初に、熱分解装置（Ｐｙ）としてキューリーポイント熱分解装置ＪＨＰ−５（日本分析工業株式会社製）を用いて画分（１５）の熱分解を行った。まず、炉内とガスクロマトグラフ導入部の温度を２５０℃にした。次に、フェロマグネティック−パイロホイル（厚さ５０μｍ）で０．１〜０．２ｍｇの画分（１５）を包み、１０％テトラメチルアンモニウムヒドロキサイドのメタノール溶液５μＬを加え、炉内に入れて３１５℃で４秒間処理することで熱分解を行った後、熱分解生成物をガスクロマトグラフ装置に導いた。なお、１０％テトラメチルアンモニウムヒドロキサイドのメタノール溶液は、画分（１５）に含まれる化学構造をメチル化することにより質量分析の段階で揮発性や熱安定性が得られるようにする目的で用いた。
ガスクロマトグラフ−マススペクトル（ＧＣ−ＭＳ）にはガスクロマトグラフ質量分析装置ＪＭＳ−６００Ｍ（日本電子株式会社製）を用いた。また、データ処理装置としてＴＳＳ−２０００（日本分析工業株式会社製）を用いた。ガスクロマトグラフ用カラムにはキャピラリーカラムＨＰ−１ＭＳ（カラム寸法：直径０．２５ｍｍ×長さ３０ｍ，コーティングした液層の厚さ：０．２５μｍ，アジレント・テクノロジー製）を用いた。画分（１５）の熱分解生成物とキャリアガスをカラム内に導入し、熱分解生成物中に存在する物質を分離するとともに、保持時間に関するデータを取得した。また、分離した各物質について質量分析を行い、化学構造などに関する知見を得た。なお、カラム内の温度は最初５０℃で１分間保持し、次に５℃／分で３００℃まで直線的に昇温させ、その後３００℃で１４分間保持した。キャリアガスにはヘリウムを用いた。流速は１ｍＬ／分に設定した。質量分析はイオン源温度２５０℃，イオン化電圧７０ｅＶの条件で行った。
ガスクロマトグラフ−マススペクトルにより得られたデータと、合成標準物質について同様の実験を行うことで得られたデータを比較した結果、画分（１５）の熱分解生成物から以下に化学式を示す１０種類の化合物が検出された。
(C) Structural analysis of fraction (15) Structural analysis of fraction (15) was performed using a pyrolysis-gas chromatograph-mass spectrum (Py-GC-MS) analyzer. According to the Py-GC-MS analyzer, after pyrolyzing a sample with a pyrolyzer (Py), the obtained pyrolyzed product is introduced into a gas chromatograph (GC) and separated, and further separated substances Can be obtained with a mass spectrum apparatus (MS) to obtain knowledge about the thermal properties and chemical structure of the sample.
First, the fraction (15) was pyrolyzed using a Curie point pyrolyzer JHP-5 (manufactured by Nippon Analytical Industrial Co., Ltd.) as the pyrolyzer (Py). First, the temperature in the furnace and the gas chromatograph introduction part was set to 250 ° C. Next, 0.1 to 0.2 mg of the fraction (15) is wrapped with ferromagnetic-pyrofoil (thickness 50 μm), 5 μL of 10% tetramethylammonium hydroxide methanol solution is added, and placed in a furnace at 315 ° C. Was subjected to pyrolysis by treating for 4 seconds, and then the pyrolysis product was led to a gas chromatograph. The methanol solution of 10% tetramethylammonium hydroxide is used for the purpose of obtaining volatility and thermal stability at the stage of mass spectrometry by methylating the chemical structure contained in fraction (15). It was.
A gas chromatograph mass spectrometer JMS-600M (manufactured by JEOL Ltd.) was used for gas chromatograph-mass spectrum (GC-MS). In addition, TSS-2000 (manufactured by Nippon Analysis Co., Ltd.) was used as a data processing device. A capillary column HP-1MS (column size: diameter 0.25 mm × length 30 m, coated liquid layer thickness: 0.25 μm, manufactured by Agilent Technologies) was used as the column for gas chromatography. The pyrolysis product of fraction (15) and the carrier gas were introduced into the column to separate the substances present in the pyrolysis product and to acquire data on the retention time. Moreover, mass spectrometry was performed about each isolate | separated substance, and the knowledge regarding chemical structure etc. was acquired. The temperature in the column was first maintained at 50 ° C. for 1 minute, then linearly increased to 300 ° C. at 5 ° C./minute, and then maintained at 300 ° C. for 14 minutes. Helium was used as the carrier gas. The flow rate was set at 1 mL / min. Mass spectrometry was performed under the conditions of an ion source temperature of 250 ° C. and an ionization voltage of 70 eV.
As a result of comparing the data obtained by gas chromatograph-mass spectrum and the data obtained by conducting the same experiment on the synthetic standard substance, the following 10 chemical formulas were obtained from the pyrolysis product of fraction (15). Of the compound was detected.
なお、上記の化合物の保持時間（ｔＲ：ｒｅｔｅｎｔｉｏｎ ｔｉｍｅ）と分子量は次の通りである。
化合物１・・・ｔＲ：２３．０分，分子量：１６８
化合物２・・・ｔＲ：２２．１分，分子量：１６６
化合物３・・・ｔＲ：３０．３分，分子量：１９６
化合物４・・・ｔＲ：３０．５分，分子量：２２６
化合物５・・・ｔＲ：３１．１分，分子量：２５４
化合物６・・・ｔＲ：３２．４分，分子量：２５４
化合物７・・・ｔＲ：３２．９分，分子量：２５４
化合物８・・・ｔＲ：３５．２分，分子量：２８４
化合物９・・・ｔＲ：３６．９分，分子量：３１２
化合物１０・・ｔＲ：４６．５分，分子量：４５０
In addition, the retention time (tR: retention time) and molecular weight of said compound are as follows.
Compound 1 ... tR: 23.0 minutes, molecular weight: 168
Compound 2 ... tR: 22.1 min, molecular weight: 166
Compound 3 tR: 30.3 minutes, molecular weight: 196
Compound 4 ... tR: 30.5 minutes, molecular weight: 226
Compound 5 ... tR: 31.1 minutes, molecular weight: 254
Compound 6 ... tR: 32.4 minutes, molecular weight: 254
Compound 7 ... tR: 32.9 minutes, molecular weight: 254
Compound 8 ... tR: 35.2 minutes, molecular weight: 284
Compound 9 ... tR: 36.9 minutes, molecular weight: 312
Compound 10 ·· tR: 46.5 minutes, molecular weight: 450
以上の結果から、画分（１５）は、上記の１０種類の熱分解生成物を与える化学構造を有する物質であることがわかった。質量分析の結果からは、この物質がカテキン類の２’位，５’位，６’位と他のカテキン類のいずれかの位置の間、例えば、カテキン類同士の８位と６’位の間，６位と６’位の間，６’位と６’位の間などに重合部位を有することが示唆された。また、別途に行った画分（１５）のタンナーゼ分解の結果からは、この物質にはエピカテキンやエピガロカテキンの３位の水酸基にエステル結合していると考えられる没食子酸残基が含まれることが示された。塩酸−ブタノール分解の結果からは、この物質は部分構造中にカテキン類同士の４位と８位の間または４位と６位の間で重合したプロシアニジン構造を含むことが推測された。以上の結果を総合的に判断すると、画分（１５）は、例えば、以下に示す、プロシアニジン構造と、カテキン類のＢ環同士が結合した構造を部分構造中に少なくとも含んでいる高分子ポリフェノールであることがわかった（なお、この高分子ポリフェノールに含まれる部分構造の種類は多種多様であると考えられ、以上の結果はベンゾトロポロン、ベンゾキノン、ナフトキノンなどを含む部分構造の存在を否定するものではない）。 From the above results, it was found that the fraction (15) is a substance having a chemical structure that gives the 10 kinds of pyrolysis products. From the results of mass spectrometry, this substance is located between the 2′-position, 5′-position and 6′-position of the catechins and any of the other catechins, for example, the 8th and 6′-positions of the catechins. It was suggested that there are polymerization sites between the 6-position and the 6'-position, between the 6'-position and the 6'-position. In addition, this substance contains a gallic acid residue that is considered to be ester-bonded to the hydroxyl group at the 3-position of epicatechin or epigallocatechin from the result of tannase degradation of fraction (15) performed separately. It was shown that. From the result of hydrochloric acid-butanol decomposition, it was speculated that this substance contained a procyanidin structure polymerized between the 4-position and 8-position or between the 4-position and 6-position of catechins in the partial structure. Comprehensively judging the above results, the fraction (15) is, for example, a polymer polyphenol that contains at least a procyanidin structure and a structure in which B rings of catechins are bonded to each other in the partial structure shown below. It was found that there are various types of partial structures contained in this polymer polyphenol, and the above results do not deny the existence of partial structures containing benzotropolone, benzoquinone, naphthoquinone, etc. Absent).
（Ｄ）画分（１５）の高分子ポリフェノールの肝脂肪に対する作用
（実験方法）
雄の６週齢のＩＩ型糖尿病モデルマウス（ＢＳＫ．Ｃｇ−ｍ＋／＋Ｌｅｐｒ＜ｄｂ＞／Ｊｃｌ，日本クレア）に、生理食塩水に溶解した高分子ポリフェノールを、投与量が０．０９ｍｇ／匹となるように毎日０．１ｍＬずつ腹腔注射した。投与開始から１０週間経過後にマウスをネンブタールで処理してから全採血した。肝臓を適当な大きさに切り出し、３．７％ホルマリン溶液で固定し、７０％エタノール溶液で脱水した後、引き続きブタノールの濃度を変えながら脱水してからパラフィン包埋した。パラフィン包埋した肝臓をミクロトームで８μｍの厚さに切り出し、スライドガラスにのせて肝臓組織切片とした。核を染色するヘマトキシリンと細胞質を染色するエオシンを用いて肝臓組織切片を染色した後、光学顕微鏡を用いて画像を取得した。得られた画像を図２に示す。また、生理食塩水を０．１ｍＬ／匹で腹腔注射したコントロールマウスの投与開始から１０週間経過後の肝臓組織切片の画像を図３に示す。
(D) Action of high molecular weight polyphenol of fraction (15) on liver fat (experimental method)
A male 6-week-old type II diabetes model mouse (BSK.Cg-m + / + Lepr <db> / Jcl, Claire, Japan) was treated with a high molecular weight polyphenol dissolved in physiological saline at a dose of 0.09 mg / animal. Each day, 0.1 mL was injected intraperitoneally. After 10 weeks from the start of administration, the mice were treated with Nembutal, and then whole blood was collected. The liver was cut into an appropriate size, fixed with a 3.7% formalin solution, dehydrated with a 70% ethanol solution, dehydrated while changing the butanol concentration, and then embedded in paraffin. The paraffin-embedded liver was cut into a thickness of 8 μm with a microtome and placed on a slide glass to obtain a liver tissue section. After staining liver tissue sections with hematoxylin for staining nuclei and eosin for staining cytoplasm, images were obtained using an optical microscope. The obtained image is shown in FIG. Further, FIG. 3 shows an image of a liver tissue section 10 weeks after the start of administration of a control mouse in which physiological saline was injected intraperitoneally at 0.1 mL / animal.
（実験結果）
図２と図３から明らかなように、画分（１５）の高分子ポリフェノールを投与したマウスの肝臓組織に含まれる脂肪は、生理食塩水を投与したコントロールマウスの肝臓組織に含まれる脂肪に比較して格段に少なかった（細かな白抜きが脂肪を表す。大きな白抜きは血管である）。また、画分（１５）の高分子ポリフェノールを投与したマウスの体重増加の程度は、コントロールマウスの体重増加の程度と大差がなく、順調に推移した。以上の結果から、画分（１５）の高分子ポリフェノールは、ＩＩ型糖尿病に起因する脂肪肝に対して優れた治療剤となることがわかった。
(Experimental result)
As is clear from FIG. 2 and FIG. 3, the fat contained in the liver tissue of the mouse administered with the high molecular weight polyphenol of fraction (15) is compared with the fat contained in the liver tissue of the control mouse administered with physiological saline. There was much less (a fine outline represents fat. A large outline is a blood vessel). Moreover, the degree of weight gain of the mice administered with the high molecular weight polyphenol of fraction (15) was not significantly different from the degree of weight gain of the control mice, and progressed smoothly. From the above results, it was found that the polymer polyphenol of the fraction (15) is an excellent therapeutic agent for fatty liver caused by type II diabetes.
実施例２：ウーロン茶から抽出される高分子ポリフェノール（その２）の脂肪肝に対する作用
実施例１の（Ａ）でブタノール溶出成分を含む抽出液を得た後に残った水相を塩酸でｐＨを約３にした後、５００ｍＬにつき２００ｍＬの水飽和ｎ−ブタノールを加え、攪拌し、静置した後、ブタノール相を分取する操作を５回繰り返した。分取したブタノール相を集めることでブタノール溶出成分を含む抽出液を得、これを減圧濃縮することで残存するブタノールを除去し、ブタノール溶出成分を含む水溶液を得た。この水溶液を凍結乾燥し、ウーロン茶ブタノール抽出酸性画分をウーロン茶葉１２０ｇあたり３．２ｇの収量で得た。このウーロン茶ブタノール抽出酸性画分を、実施例１の（Ａ）と同様にして細かく分画し、１５個の画分サンプルを得た。図４にウーロン茶ブタノール抽出酸性画分の溶出曲線（溶出パターン）を示す（横軸：溶出液を回収した試験管番号（回収順），縦軸：３５０ｎｍにおける吸光度）。また、溶出曲線に基づいて細分画して得た１５個の画分を図４にあわせて示す。実施例１の（Ｂ）と同様にしてサイズ排除クロマトグラフィー法により画分（１４）の高分子ポリフェノールの平均分子量を測定したところ、数平均分子量は１．７３×１０４、重量平均分子量は２．４４×１０４であった。この画分（１４）の高分子ポリフェノールの脂肪肝に対する作用を実施例１の（Ｄ）と同様にして評価したところ、実施例１の画分（１５）の高分子ポリフェノールと同様の作用が認められた。
Example 2: Effect of macromolecular polyphenol extracted from oolong tea (part 2) on fatty liver The aqueous phase remaining after obtaining the butanol-eluting component in Example 1 (A) was adjusted to about pH with hydrochloric acid. Then, 200 mL of water-saturated n-butanol was added to 500 mL, and the mixture was stirred and allowed to stand, and then the butanol phase was separated five times. By collecting the separated butanol phase, an extract containing a butanol-eluting component was obtained, and this was concentrated under reduced pressure to remove the remaining butanol, thereby obtaining an aqueous solution containing a butanol-eluting component. This aqueous solution was freeze-dried to obtain an acidic fraction extracted from oolong tea butanol with a yield of 3.2 g per 120 g of oolong tea leaves. This oolong tea butanol-extracted acidic fraction was finely fractionated in the same manner as in Example 1 (A) to obtain 15 fraction samples. FIG. 4 shows an elution curve (elution pattern) of an acidic fraction extracted from oolong tea butanol (horizontal axis: test tube number from which the eluate was collected (in order of collection), vertical axis: absorbance at 350 nm). 15 fractions obtained by subfractionation based on the elution curve are also shown in FIG. When the average molecular weight of the high molecular weight polyphenol of the fraction (14) was measured by the size exclusion chromatography method in the same manner as in Example 1 (B), the number average molecular weight was 1.73 × 10 4 and the weight average molecular weight was 2. .44 × 10 4 . When the action of this fraction (14) on the fatty liver of the polymer polyphenol was evaluated in the same manner as in Example 1 (D), the same action as that of the polymer polyphenol in fraction (15) of Example 1 was observed. It was.
実施例３：紅茶から抽出される高分子ポリフェノール（その１）の脂肪肝に対する作用
沸騰水５００ｍＬに紅茶葉２５ｇを加え、１０分間穏やかに沸騰後、直ちにブフナーロートとで紅茶葉をろ過して除去し、ろ液を得た。以上の操作を合計４回行い、紅茶葉１００ｇから水溶出成分を含む水溶液を得た。以降の操作を実施例１の（Ａ）と同様にして紅茶ブタノール抽出中性画分を紅茶葉１００ｇあたり１．５ｇの収量で得た。この紅茶ブタノール抽出中性画分を、実施例１の（Ａ）と同様にして細かく分画し、１６個の画分サンプルを得た。図５に紅茶ブタノール抽出中性画分の溶出曲線（溶出パターン）を示す（横軸：溶出液を回収した試験管番号（回収順），縦軸：３５０ｎｍにおける吸光度）。また、溶出曲線に基づいて細分画して得た１６個の画分を図５にあわせて示す。実施例１の（Ｂ）と同様にしてサイズ排除クロマトグラフィー法により画分（１５）の高分子ポリフェノールの平均分子量を測定したところ、数平均分子量は１．３６×１０４、重量平均分子量は１．８９×１０４であった。この画分（１５）の高分子ポリフェノールの脂肪肝に対する作用を実施例１の（Ｄ）と同様にして評価したところ、実施例１の画分（１５）の高分子ポリフェノールと同様の作用が認められた。
Example 3: Effect of high molecular polyphenol extracted from black tea (part 1) on fatty liver Add 25 g of black tea leaf to 500 mL of boiling water, boil gently for 10 minutes, and immediately filter and remove black tea leaf with Buchner funnel The filtrate was obtained. The above operation was performed 4 times in total to obtain an aqueous solution containing a water-eluting component from 100 g of black tea leaves. The subsequent operation was carried out in the same manner as in Example 1 (A), and a black fraction extracted with black tea butanol was obtained at a yield of 1.5 g per 100 g of black tea leaves. This black butanol-extracted neutral fraction was finely fractionated in the same manner as in Example 1 (A) to obtain 16 fraction samples. FIG. 5 shows the elution curve (elution pattern) of the neutral fraction extracted from black tea butanol (horizontal axis: test tube number from which the eluate was collected (in order of collection), vertical axis: absorbance at 350 nm). In addition, 16 fractions obtained by subfractionation based on the elution curve are shown in FIG. When the average molecular weight of the high molecular weight polyphenol of the fraction (15) was measured by the size exclusion chromatography method in the same manner as in Example 1 (B), the number average molecular weight was 1.36 × 10 4 and the weight average molecular weight was 1. It was 89 × 10 4 . When the effect of this fraction (15) on the fatty liver of the polymer polyphenol was evaluated in the same manner as in Example 1 (D), the effect similar to that of the polymer polyphenol in fraction (15) of Example 1 was observed. It was.
実施例４：紅茶から抽出される高分子ポリフェノール（その２）の脂肪肝に対する作用
実施例２と同様にして紅茶ブタノール抽出酸性画分を紅茶葉１００ｇあたり１．９ｇの収量で得た。この紅茶ブタノール抽出酸性画分を、実施例１の（Ａ）と同様にして細かく分画し、１１個の画分サンプルを得た。図６に紅茶ブタノール抽出酸性画分の溶出曲線（溶出パターン）を示す（横軸：溶出液を回収した試験管番号（回収順），縦軸：３５０ｎｍにおける吸光度）。また、溶出曲線に基づいて細分画して得た１１個の画分を図６にあわせて示す。実施例１の（Ｂ）と同様にしてサイズ排除クロマトグラフィー法により画分（１１）の高分子ポリフェノールの平均分子量を測定したところ、数平均分子量は９．４３×１０３、重量平均分子量は１．４８×１０４であった。この画分（１１）の高分子ポリフェノールの脂肪肝に対する作用を実施例１の（Ｄ）と同様にして評価したところ、実施例１の画分（１５）の高分子ポリフェノールと同様の作用が認められた。
Example 4: Effect of high molecular polyphenol extracted from black tea (part 2) on fatty liver In the same manner as in Example 2, an acidic fraction extracted from black tea butanol was obtained in a yield of 1.9 g per 100 g of black tea leaves. The black tea butanol-extracted acidic fraction was finely fractionated in the same manner as in Example 1 (A) to obtain 11 fraction samples. FIG. 6 shows an elution curve (elution pattern) of the acidic fraction extracted from black tea butanol (horizontal axis: test tube number from which the eluate was collected (in order of collection), vertical axis: absorbance at 350 nm). In addition, 11 fractions obtained by subfractionation based on the elution curve are shown in FIG. When the average molecular weight of the high molecular weight polyphenol of the fraction (11) was measured by the size exclusion chromatography method in the same manner as in Example 1 (B), the number average molecular weight was 9.43 × 10 3 and the weight average molecular weight was 1. 48 × 10 4 . When the action of this fraction (11) on the fatty liver of the polymer polyphenol was evaluated in the same manner as in Example 1 (D), the same action as that of the polymer polyphenol in fraction (15) of Example 1 was observed. It was.
実施例５：脂肪肝に対する実施例１の画分（１５）の高分子ポリフェノールの経口投与による作用
雄の６週齢のＩＩ型糖尿病モデルマウス（ＢＳＫ．Ｃｇ−ｍ＋／＋Ｌｅｐｒ＜ｄｂ＞／Ｊｃｌ，日本クレア）に、実施例１の画分（１５）の高分子ポリフェノールを０．０２％の濃度で含む水を１０週間自由に飲ませた。また、エピガロカテキンガレートを０．０２％の濃度で含む水と、何も含まない水を、それぞれ別のマウスに１０週間自由に飲ませた。１０週間経過後、それぞれのマウスの脂肪肝に対する作用を実施例１の（Ｄ）と同様にして評価した。結果を図７に示す。図中、（ａ）は何も含まない水を投与したマウス、（ｂ）は実施例１の画分（１５）の高分子ポリフェノールを含む水を投与したマウス、（ｃ）はエピガロカテキンガレートを含む水を投与したマウスの結果を示す。図７から明らかなように、エピガロカテキンガレートを含む水を投与したマウスの肝臓組織に含まれる脂肪は、何も含まない水を投与したマウスの脂肪組織に含まれる脂肪とほとんど変わりがなかったが、実施例１の画分（１５）の高分子ポリフェノールを含む水を投与したマウスの肝臓組織に含まれる脂肪は、何も含まない水を投与したマウスの脂肪組織に含まれる脂肪に比較して格段に少なかった（細かな白抜きが脂肪を表す。大きな白抜きは血管である）。
また、１０週間経過後、実施例１の画分（１５）の高分子ポリフェノールを含む水を投与したマウス、エピガロカテキンガレートを含む水を投与したマウス、何も含まない水を投与したマウスのそれぞれについて各種の項目を測定した（ｎ＝５〜６）。その結果は次の通りである。実施例１の画分（１５）の高分子ポリフェノールを含む水を投与したマウスは、何も含まない水を投与したマウスと比較して、体重増加と血糖値上昇が有意に抑制されたが、このような現象はエピガロカテキンガレートを含む水を投与したマウスでは見られなかった。実施例１の画分（１５）の高分子ポリフェノールを含む水を投与したマウスは、何も含まない水を投与したマウスと比較して、摂餌量が有意に多いにもかかわらず、内臓脂肪量が有意に少なかったが、このような現象はエピガロカテキンガレートを含む水を投与したマウスでは見られなかった。実施例１の画分（１５）の高分子ポリフェノールを含む水を投与したマウスは、何も含まない水を投与したマウスと比較して、血漿中の総コレステロールレベルと遊離脂肪酸レベルが有意に低く、中性脂肪レベルも有意差はないものの低かったが、このような現象はエピガロカテキンガレートを含む水を投与したマウスでは見られなかった。
以上の結果から、実施例１の画分（１５）の高分子ポリフェノールは、それ自身あるいはそれが腸内で分解されてから、腸管を通過して体内に取り込まれ、肝機能障害などを引き起こすことなく、脂肪肝を改善することがわかった。
Example 5: Effect of Oral Administration of Fraction (15) of Example 1 on Fatty Liver Male 6-week-old Type II Diabetes Model Mouse (BSK.Cg-m + / + Lepr <db> / Jcl, Nippon Claire) was allowed to freely drink water containing a high-molecular polyphenol of fraction (15) of Example 1 at a concentration of 0.02% for 10 weeks. Also, water containing epigallocatechin gallate at a concentration of 0.02% and water containing nothing were allowed to freely drink for 10 weeks respectively. After 10 weeks, the effect of each mouse on fatty liver was evaluated in the same manner as in Example 1 (D). The results are shown in FIG. In the figure, (a) is a mouse administered with water containing nothing, (b) is a mouse administered with water containing the polymer polyphenol of fraction (15) of Example 1, and (c) is epigallocatechin gallate. The result of the mouse | mouth which administered water containing is shown. As is clear from FIG. 7, the fat contained in the liver tissue of the mouse administered with water containing epigallocatechin gallate was almost the same as the fat contained in the fat tissue of the mouse administered with water containing nothing. However, the fat contained in the liver tissue of the mouse administered with water containing the high molecular weight polyphenol of fraction (15) of Example 1 was compared with the fat contained in the fat tissue of the mouse administered with water containing nothing. There was much less (a fine white outline represents fat. A large white outline is a blood vessel).
In addition, after 10 weeks, the mice administered with water containing the polymer polyphenol of fraction (15) of Example 1, the mice administered with water containing epigallocatechin gallate, and the mice administered with water containing nothing. Various items were measured for each (n = 5-6). The results are as follows. The mice administered with water containing the high molecular weight polyphenol of fraction (15) of Example 1 were significantly suppressed in weight gain and blood glucose level compared to mice administered with water containing nothing, Such a phenomenon was not observed in mice administered with water containing epigallocatechin gallate. Although the mice administered with water containing the high molecular weight polyphenol of fraction (15) of Example 1 had significantly higher food intake compared to mice administered with water containing nothing, visceral fat Although the amount was significantly lower, such a phenomenon was not seen in mice administered water containing epigallocatechin gallate. Mice administered with water containing the polymeric polyphenol of fraction (15) of Example 1 have significantly lower plasma total cholesterol levels and free fatty acid levels than mice administered with water containing nothing. The level of triglycerides was also low, although there was no significant difference, but this phenomenon was not observed in mice administered with water containing epigallocatechin gallate.
From the above results, the high-molecular polyphenol of fraction (15) of Example 1 itself or itself is degraded in the intestine, and then taken into the body through the intestinal tract, causing liver dysfunction and the like. Not found to improve fatty liver.
製剤例１：錠剤
実施例１の画分（１５）の高分子ポリフェノールの凍結乾燥粉末５ｇ、乳糖７８ｇ、ステアリン酸マグネシウム１７ｇ、合計１００ｇを均一に混合し、常法に従って錠剤とした。
Formulation Example 1: Tablet 5 g of lyophilized powder of high molecular weight polyphenol of fraction (15) of Example 1, 78 g of lactose and 17 g of magnesium stearate were uniformly mixed to obtain tablets according to a conventional method.
製剤例２：ビスケット
薄力粉３１ｇ、全卵１６ｇ、バター１６ｇ、砂糖２４ｇ、水１０ｇ、ベーキングパウダー１ｇ、実施例３の画分（１５）の高分子ポリフェノールの凍結乾燥粉末２ｇ、合計１００ｇを用い、常法に従ってビスケットとした。
Formulation Example 2: Biscuit Soft flour 31 g, whole egg 16 g, butter 16 g, sugar 24 g, water 10 g, baking powder 1 g, fraction 3 of Example 3 (15) high-molecular polyphenol lyophilized powder 2 g, 100 g in total. Biscuits were made according to the law.
本発明は、天然由来の脂肪肝の予防および／または治療剤を提供することができる点において産業上の利用可能性を有する。 The present invention has industrial applicability in that a prophylactic and / or therapeutic agent for naturally occurring fatty liver can be provided.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007121049A JP5441046B2 (en) | 2006-05-01 | 2007-05-01 | Preventive and / or therapeutic agent for fatty liver |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006127897 | 2006-05-01 | ||
| JP2006127897 | 2006-05-01 | ||
| JP2007121049A JP5441046B2 (en) | 2006-05-01 | 2007-05-01 | Preventive and / or therapeutic agent for fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007320958A true JP2007320958A (en) | 2007-12-13 |
| JP5441046B2 JP5441046B2 (en) | 2014-03-12 |
Family
ID=38854067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007121049A Expired - Fee Related JP5441046B2 (en) | 2006-05-01 | 2007-05-01 | Preventive and / or therapeutic agent for fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5441046B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009179579A (en) * | 2008-01-30 | 2009-08-13 | Seiko:Kk | Lipase inhibitor, and composition comprising the same |
| JP2009242374A (en) * | 2008-03-14 | 2009-10-22 | Miyazakiken Sangyo Shien Zaidan | Hepatic fibrosis inhibitory agent |
| JP2012005413A (en) * | 2010-06-24 | 2012-01-12 | Osamu Numata | Method for preparing fermented tea extract containing polymer polyphenol |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005523242A (en) * | 2001-11-28 | 2005-08-04 | ナシャイ・バイオテック・リミテッド・ライアビリティ・カンパニー | Preparation and use of theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| WO2005077384A1 (en) * | 2004-02-17 | 2005-08-25 | Suntory Limited | Lipase activity inhibitor containing high-molecular weight polyphenol fraction, tea extract and process for producing the same |
-
2007
- 2007-05-01 JP JP2007121049A patent/JP5441046B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005523242A (en) * | 2001-11-28 | 2005-08-04 | ナシャイ・バイオテック・リミテッド・ライアビリティ・カンパニー | Preparation and use of theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| WO2005077384A1 (en) * | 2004-02-17 | 2005-08-25 | Suntory Limited | Lipase activity inhibitor containing high-molecular weight polyphenol fraction, tea extract and process for producing the same |
Non-Patent Citations (5)
| Title |
|---|
| JPN6012045679; 韓立坤 外５名: '"茶の抗肥満作用について"' 日本栄養・食糧学会総会講演要旨集 Ｖｏｌ．５３ｒｄ, 19990420, Ｐ．５２ * |
| JPN6012045681; 豊川哲也 外１名: '"モクセンナのリパーゼ阻害活性作用による抗肥満効果および脂肪肝改善効果"' 平成１５年度沖縄県工業技術センター研究報告書 第６号, 200408, Ｐ．１０１-１０６ * |
| JPN6012045683; 武田忠明 外４名: '"サケ鼻軟骨由来コンドロイチン硫酸の抗肥満作用とその機序"' 日本栄養・食糧学会誌 Ｖｏｌ．５２，Ｎｏ．６, 19991210, Ｐ．３８１-３８６ * |
| JPN6013032270; Ｈａｎ，Ｌ．Ｋ． ｅｔ ａｌ．: 'Ａｎｔｉ-ｏｂｅｓｉｔｙ ａｃｔｉｏｎ ｏｆ ｏｏｌｏｎｇ ｔｅａ' Ｉｎｔ． Ｊ． Ｏｂｅｓ． Ｖｏｌ．２３，Ｎｏ．１, 199901, Ｐ．９８-１０５ * |
| JPN6013032272; 岩田多子 外２名: '報文"果糖誘導性高脂血症ラットの血漿ならびに肝臓脂質代謝に及ぼす中国緑茶，烏龍茶，紅茶の影響"' 栄養学雑誌 Ｖｏｌ．４６，Ｎｏ．６, 1988, Ｐ．２８９-２９８, 日本栄養改善学会 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009179579A (en) * | 2008-01-30 | 2009-08-13 | Seiko:Kk | Lipase inhibitor, and composition comprising the same |
| JP2009242374A (en) * | 2008-03-14 | 2009-10-22 | Miyazakiken Sangyo Shien Zaidan | Hepatic fibrosis inhibitory agent |
| JP2012005413A (en) * | 2010-06-24 | 2012-01-12 | Osamu Numata | Method for preparing fermented tea extract containing polymer polyphenol |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5441046B2 (en) | 2014-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5439644B2 (en) | Blood sugar level increase inhibitor and mitochondrial membrane potential increase agent extracted from oolong tea or black tea | |
| Bitzer et al. | Cocoa procyanidins with different degrees of polymerization possess distinct activities in models of colonic inflammation | |
| US9089595B2 (en) | Extract of Rehmannia glutinasa Libosch. for reducing blood glucose and lipid levels and treating hematologic diseases, and methods for preparing the same | |
| Xing et al. | Simulated gastrointestinal tract metabolism and pharmacological activities of water extract of Scutellaria baicalensis roots | |
| X Liu et al. | Extraction and characterization of proanthocyanidins from grape seeds | |
| EP2923705B1 (en) | Beautyberry total glycosides extract and preparation method and use thereof | |
| Zheng et al. | Composition and serum antioxidation of the main flavonoids from fermented vine tea (Ampelopsis grossedentata) | |
| Qiu et al. | Semen hoveniae extract ameliorates alcohol-induced chronic liver damage in rats via modulation of the abnormalities of gut-liver axis | |
| Liu et al. | Antioxidant, anti-inflammatory, and antiproliferative activities of Taxillus sutchuenensis | |
| Shen et al. | Lipophilic phenols partially explain differences in the antioxidant activity of subfractions from methanol extract of camellia oil | |
| US20150196498A1 (en) | Hydroxytrosol containing extract obtained from olives and solids containing residues of olive oil extraction | |
| CN107854507B (en) | Method for extracting flavonoid component from folium artemisiae argyi | |
| Wakamatsu et al. | Antioxidative Maillard reaction products generated in processed aged garlic extract | |
| JP5441046B2 (en) | Preventive and / or therapeutic agent for fatty liver | |
| Jack et al. | Polyphenol-enriched fractions of cyclopia intermedia selectively affect lipogenesis and Lipolysis in 3T3-L1 adipocytes | |
| AU2013210416B2 (en) | Desrhamnosyl acteoside-containing olive extract | |
| Kruk et al. | Tiliae flos metabolites and their beneficial influence on human gut microbiota biodiversity ex vivo | |
| Farias et al. | In vitro free radical scavenging properties and anti-inflammatory activity of Ilex paraguariensis (Maté) and the ability of its major chemical markers to inhibit the production of proinflammatory mediators | |
| CN107708717B (en) | Application of rhinacanthin quinone C as nerve cell apoptosis inhibitor | |
| JP2012005413A (en) | Method for preparing fermented tea extract containing polymer polyphenol | |
| Costa et al. | One-step isolation of monoterpene indole alkaloids from Psychotria leiocarpa leaves and their antiviral activity on Dengue Virus type-2 | |
| Quartey et al. | Hydroethanolic stem bark extract of Vernonia amygdalina Del.(Asteraceae) suppresses yeast-induced pyrexia and Plasmodium berghei malaria in murine models | |
| JP2010037323A (en) | Promotor to shift muscle into slow muscle | |
| JP2009029752A (en) | Formation inhibitor for abnormal type prion protein | |
| KR101545495B1 (en) | Pharmaceutical Composition and Functional Food for Preventing or Treating Neurodegenerative Disease by Saururus Chinesis Extracts and Quercetin as Effective Component, and Extracting Method of Saururus Chinesis Extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100506 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100506 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100506 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121102 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131024 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131203 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131210 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5441046 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |